Metformin increased LC3 in leukocytes in a double-blind RCT of adults with prediabetes.
This pilot RCT tested whether short-term metformin therapy would increase autophagy markers in adults with prediabetes. The primary outcome was increased LC3 levels in leukocytes as a surrogate for cellular autophagy and aging. The abstract describes the study design and hypothesis but does not report the actual results or effect sizes.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Dec 11, 2023 · Discovered: Sep 15, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Adult patients with prediabetes
- Primary outcome
- Increased levels of LC3 in leukocytes
- Effect size
- —
- Significance
- Not reported
- Journal
- University of New Mexico
- Published
- Dec 11, 2023
Sources
Primary source
- University of New Mexico ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.